Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pilocarpine + phentolamine
- Development stage
- Unknown
- Lead developer
- Opus Genetics
- Modality
- Small Molecules
- Administration
- Ophthalmic
01
Overview
**Pilocarpine + phentolamine** is an ophthalmic fixed-dose combination developed as an eye drop formulation to address **presbyopia**. It contains pilocarpine, a muscarinic acetylcholine receptor agonist (miotic), and phentolamine, a reversible, non-selective alpha-1 and alpha-2 adrenergic receptor antagonist. Pilocarpine acts by constricting the pupil (miosis) through stimulation of muscarinic receptors, enhancing near vision in presbyopic patients. Phentolamine reduces pupillary diameter by blocking adrenergic receptors on the iris dilator muscle, further supporting improvement in near and intermediate visual acuity while potentially minimizing night vision disturbances. The combination has been studied, including in phase 3 clinical trials, for presbyopia and reversal of pharmacological mydriasis, and is under development by Opus Genetics (originator Ocuphire Pharma)[1][3][5][7][9].
- Brand names
- Nyxol + Low-Dose Pilocarpine Eye Drops
- Other names
- pilocarpine/phentolamineNyxol + pilocarpine
02
Targets
M1 (Muscarinic acetylcholine receptor M1)ADRA1A (α1A)CHRM3 (M3)ADRA2 (Alpha-2 adrenergic receptor family)CHRM2 (M2)
Beyond the preview
Go deeper on pilocarpine + phentolamine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pilocarpine + phentolamine.